Skip to main content
. Author manuscript; available in PMC: 2017 Sep 29.
Published in final edited form as: J Evol Stem Cell Res. 2017 Jan 24;1(2):1–11. doi: 10.14302/issn.2574-4372.jesr-16-1395

Figure 2.

Figure 2

Analysis of CaT profiles drug-treated iPSC-derived cardiomyocytes measured using FLIPR and Cal-520 calcium dye. FLIPR and Cal-520 loaded iPSC-derived cardiomyocytes treated with increasing concentrations of dofetilide and E4031 and analysis of (A) average traces, (B) and (D) amplitude, (C) and (E) CaT duration-90. Asterix (*) indicates a significant difference (P<0.05) from vehicle-treated groups by t-test analysis and a number above the bar indicates the fraction of the total number of wells where traces showed EAD and were not included in the analysis. Percent changes were computed by 100 X (Treated Read3-Pretreated Read2)/(Pretreated Read2) for each well. There was no significant difference between no treatment and vehicle treated groups.